SCHEMBL23925787

SCHEMBL23925787

COc1cc(Oc2nc(-c3cccc(OC)c3F)ccc2C(=O)Cl)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
HSD17B14 Q9BPX1 1/20 0.38
DHODH Q02127 2/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
GRM4 Q14833 1/20 0.38
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
KDM1A O60341 1/20 0.37
PDCD1LG2 Q9BQ51 4/20 0.37
CD274 Q9NZQ7 4/20 0.37
POLQ O75417 1/20 0.36
PYGL P06737 1/20 0.36
PYGM P11217 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23943225 0.91 PLG (0.44) ADORA2AADORA1HSD17B14DHODHPLG
SCHEMBL23925778 0.90 CD274 (0.46) ADORA2AADORA1HSD17B14DHODHPLG
SCHEMBL3749641 0.80 DHODH (0.45) ADORA2AADORA1DHODHPDCD1LG2CD274
SCHEMBL23943229 0.77 HSD17B14 (0.59) ADORA2AADORA1HSD17B14GRM4KDM1A
SCHEMBL3747145 0.76 CD274 (0.38) ADORA2AADORA1DHODHKDM1APDCD1LG2
SCHEMBL3759883 0.74 KMO (0.46) DHODHPDCD1LG2CD274
SCHEMBL3754181 0.73 PLG (0.43) PLGPLAUPDCD1LG2CD274PYGL
SCHEMBL3759586 0.72 HTT (0.47) DHODHPDCD1LG2CD274CCNT1CDK9
SCHEMBL3757716 0.71 EIF4E (0.39) HSD17B14DHODHF10CD274
SCHEMBL3755649 0.71 DHODH (0.47) ADORA2AADORA1DHODHKDM1APDCD1LG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 ADORA2A 4678/4885ADORA1 4623/4885HSD17B14 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.